Predicting enrollment performance of investigational centers in phase III multi-center clinical trials

Publication date

2017-09-01

Authors

van den Bor, Rutger M
Grobbee, D.E.ORCID 0000-0003-4472-4468ISNI 0000000030206553
Oosterman, Bas J
Vaessen, Petrus W J
Roes, Kit C.B.ORCID 0000-0002-6775-1963ISNI 0000000040154793

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by_nc_nd

Abstract

Failure to meet subject recruitment targets in clinical trials continues to be a widespread problem with potentially serious scientific, logistical, financial and ethical consequences. On the operational level, enrollment-related issues may be mitigated by careful site selection and by allocating monitoring or training resources proportionally to the anticipated risk of poor enrollment. Such procedures require estimates of the expected recruitment performance that are sufficiently reliable to allow centers to be sensibly categorized. In this study, we investigate whether information obtained from feasibility questionnaires can potentially be used to predict which centers will and which centers will not meet their enrollment targets by means of multivariable logistic regression analysis. From a large set of 59 candidate predictors, we determined the subset that is optimal for predictive purposes using Least Absolute Shrinkage and Selection Operator (LASSO) regularization. Although the extent to which the results are generalizable remains to be determined, they indicate that the prediction accuracy of the optimal model is only a marginal improvement over the intercept-only model, illustrating the difficulty of prediction in this setting.

Keywords

Feasibility studies, Risk-based monitoring, Site performance prediction, Site questionnaires, Trial accrual, Trial recruitment, General Medicine, Pharmacology

Citation

van den Bor, R M, Grobbee, D E, Oosterman, B J, Vaessen, P W J & Roes, K C B 2017, 'Predicting enrollment performance of investigational centers in phase III multi-center clinical trials', Contemporary clinical trials communications, vol. 7, pp. 208-216. https://doi.org/10.1016/j.conctc.2017.07.004